請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37703
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 呂勝春(Sheng-Chung Lee) | |
dc.contributor.author | Wei-Ling Lin | en |
dc.contributor.author | 林韋伶 | zh_TW |
dc.date.accessioned | 2021-06-13T15:39:30Z | - |
dc.date.available | 2009-08-13 | |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-09 | |
dc.identifier.citation | Athar, U., and Gentile, T.C. (2008). Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 15, 3954-3966.
Cardone, R.A., Bellizzi, A., Busco, G., Weinman, E.J., Dell'Aquila, M.E., Casavola, V., Azzariti, A., Mangia, A., Paradiso, A., and Reshkin, S.J. (2007). The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 18, 1768-1780. Dai, J.L., Wang, L., Sahin, A.A., Broemeling, L.D., Schutte, M., and Pan, Y. (2004). NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene 23, 8681-8687. Fouassier, L., Duan, C.Y., Feranchak, A.P., Yun, C.H., Sutherland, E., Simon, F., Fitz, J.G., and Doctor, R.B. (2001). Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology 33, 166-176. Fraenzer, J.T., Pan, H., Minimo, L., Jr., Smith, G.M., Knauer, D., and Hung, G. (2003). Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23, 1493-1500. Grabowski, M., Huzarski, T., Lubinski, J., and Sikorski, A. (2002). Survival in patients with rare subtypes of renal cell carcinoma. BJU Int 89, 599-600. Gupta, G.P., and Massague, J. (2006). Cancer metastasis: building a framework. Cell 127, 679-695. Hutson, T.E., and Figlin, R.A. (2007). Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 21, 1175-1180; discussion 1184, 1187, 1190. Kerjaschki, D., Sharkey, D.J., and Farquhar, M.G. (1984). Identification and characterization of podocalyxin--the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 98, 1591-1596. Kershaw, D.B., Thomas, P.E., Wharram, B.L., Goyal, M., Wiggins, J.E., Whiteside, C.I., and Wiggins, R.C. (1995). Molecular cloning, expression, and characterization of podocalyxin-like protein 1 from rabbit as a transmembrane protein of glomerular podocytes and vascular endothelium. J Biol Chem 270, 29439-29446. Kreimann, E.L., Morales, F.C., de Orbeta-Cruz, J., Takahashi, Y., Adams, H., Liu, T.J., McCrea, P.D., and Georgescu, M.M. (2007). Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene 26, 5290-5299. McNagny, K.M., Pettersson, I., Rossi, F., Flamme, I., Shevchenko, A., Mann, M., and Graf, T. (1997). Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol 138, 1395-1407. Motzer, R.J., Bander, N.H., and Nanus, D.M. (1996). Renal-cell carcinoma. N Engl J Med 335, 865-875. Oudard, S., George, D., Medioni, J., and Motzer, R. (2007). Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 18 Suppl 10, x25-31. Pan, Y., Wang, L., and Dai, J.L. (2006). Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res 8, R63. Pan, Y., Weinman, E.J., and Dai, J.L. (2008). Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res 10, R5. Shenolikar, S., and Weinman, E.J. (2001). NHERF: targeting and trafficking membrane proteins. Am J Physiol Renal Physiol 280, F389-395. Shibata, T., Chuma, M., Kokubu, A., Sakamoto, M., and Hirohashi, S. (2003). EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 38, 178-186. Somasiri, A., Nielsen, J.S., Makretsov, N., McCoy, M.L., Prentice, L., Gilks, C.B., Chia, S.K., Gelmon, K.A., Kershaw, D.B., Huntsman, D.G., McNagny, K.M., and Roskelley, C.D. (2004). Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64, 5068-5073. Song, J., Bai, J., Yang, W., Gabrielson, E.W., Chan, D.W., and Zhang, Z. (2007). Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. Histopathology 51, 40-53. Steeg, P.S. (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12, 895-904. Stemmer-Rachamimov, A.O., Wiederhold, T., Nielsen, G.P., James, M., Pinney-Michalowski, D., Roy, J.E., Cohen, W.A., Ramesh, V., and Louis, D.N. (2001). NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol 158, 57-62. Takahashi, Y., Morales, F.C., Kreimann, E.L., and Georgescu, M.M. (2006). PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 25, 910-920. Voltz, J.W., Weinman, E.J., and Shenolikar, S. (2001). Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene 20, 6309-6314. Yagoda, A., Abi-Rached, B., and Petrylak, D. (1995). Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22, 42-60. Yu, C.Y., Chen, J.Y., Lin, Y.Y., Shen, K.F., Lin, W.L., Chien, C.L., ter Beest, M.B., and Jou, T.S. (2007). A bipartite signal regulates the faithful delivery of apical domain marker podocalyxin/Gp135. Mol Biol Cell 18, 1710-1722. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37703 | - |
dc.description.abstract | 背景:成人惡性腫瘤中,起源於腎小管上皮的腎細胞癌約佔百分之三。由於已轉移的腎細胞癌患者對於化學治療與放射線治療的成效不彰,目前發展中的分子標靶治療則有賴於癌症轉移機制的瞭解。廣泛表現於上皮細胞的EBP50是一連結蛋白,透過連結膜蛋白與細胞骨架調控訊息傳遞。近年研究指出EBP50與腫瘤新生過程有關,但它究竟是致癌基因還是抑癌基因則未有定論。於是我們著手研究EBP50在腎細胞癌中的生理意義。
方法:我們以免疫組織化學染色方法評估EBP50在305位接受腎切除手術的腎細胞癌患者之腫瘤組織的表現模式,並將EBP50在細胞質或細胞核中的表現程度分別與病人之臨床病理資料做相關性的統計分析。再以單變數分析EBP50的表現模式及各危險因子對轉移或存活的影響。 結果:在305個腎細胞癌患者的腫瘤組織中,有117個 (38.4%)細胞質呈現EBP50強陽性,這樣的患者較易發生癌症轉移 (p=0.03);相反地,有65個 (21.3%)細胞核呈現EBP50強陽性的患者癌症轉移的風險較低 (p=0.043)。EBP50聚集在細胞質與腫瘤的細胞核分化分級有明顯的統計相關 (p=0.015),類似的關係也可在細胞核呈EBP50陰性表現的腫瘤組織見到 (p=0.003)。以Kaplan-Meier方法得到的存活曲線發現只表現EBP50細胞質陽性顯然比只表現細胞核陽性的患者其無轉移存活期間明顯較短 (p=0.03)。EBP50的表現模式則與其他的危險因子,諸如性別、年齡、腫瘤大小、腫瘤分期與淋巴結轉移與否無關。 為了進一步研究EBP50在腎細胞癌中的分子機制,我們將主要表現於細胞質而不進細胞核的Flag-EBP50_dEB轉殖入腎細胞癌細胞株CRL-1933中,觀察細胞遷移與增生的能力是否改變。結果顯示EBP50在細胞質累聚將增加細胞遷移的能力,但對於細胞增生則無幫助。本篇研究證實腎細胞癌患者的腫瘤組織中若有EBP50大量表現在細胞質而不在細胞核之情形,則較容易發生轉移,其無轉移存活期間也較短。 | zh_TW |
dc.description.abstract | Renal cell carcinoma (RCC) accounts for 3% of adult malignancy and arises form renal tubular epithelium. The development of therapeutic modality against defined molecular target has been in a great demand since RCC patients with distant metastasis are notoriously resistant to chemotherapy and radiotherapy. Ezrin-radixin-moesin binding phosphoprotein 50 (EBP50) is initially identified from polarized epithelial cells as an adaptor protein linking integral membrane protein with cortical cytoskeleton. EBP50 also plays an important role in Wnt signaling pathway to promote cell proliferation. Recently, the expression patterns of EBP50 in human cancers have been addressed before, but functional characterization of EBP50 in RCC tumorigenesis is still controversial. To reveal its pathophysiological relevance, this study examined the expression pattern of EBP50 in a cohort of human renal cell carcinoma.
Methods: Three hundred and five RCC tissue specimens were examined by immunohistochemistry (IHC) and the subcellular expression pattern of EBP50 was correlated with standard clinicopathological parameters. Results: Aberrant cytoplasmic expression of EBP50 was detected in 117 (38.4%) RCC patients who had significantly increased the latent metastasis potential (p=0.03). By contrast, 65 (21.3%) RCC patients, who displayed nuclear EBP50 immunoreactivity, exhibited lower metastasis potential (p=0.04). Cytoplasmic accumulation of EBP50 was found in RCC with higher nuclear grading (p=0.015), and the association is contrary to the nuclear localization of EBP50 (p=0.003) By Kaplan-Meier analysis, the metastasis-free survival of RCC patients with strong cytosolic EBP50 expression is significantly shorter than those with nuclear EBP50 immunoreactivity (p=0.03) . However, cellular expression pattern of EBP50 did not correlate with average age at time point of diagnosis, sex, tumor size, tumor staging and lymph node metastasis. To reveal the molecular mechanism underlying the effect of EBP50 subcellular localization on cell migration and proliferating behaviors, Flag-EBP50_dEB, which expressed mainly in cytoplasm but not in nucleus, was stably expressed in human RCC cell line (CRL-1933). According to the results of wound healing, transwell, MTS assay and FACScan, the cytoplasmic accumulation of EBP50 increases migration ability and seems to have defective proliferation. This study provides observations implying that cytosolic expressed EBP50 promotes metastasis in RCC patients. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:39:30Z (GMT). No. of bitstreams: 1 ntu-97-P95448004-1.pdf: 942048 bytes, checksum: 73b0215b81c20aa59f1df96a507be63f (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 1. Table of Content…………………………………………………1
2. Abstract………………………………………………………………4 3. Key words……………………………………………………………6 4.中文摘要………………………………………………………………7 5. Introduction…………………………………………………………9 6. Materials and Methods……………………………………………12 6.1 Patient selection and tumor samples……………………12 6.2 Polyclonal anti-EBP50 antibody production and purification………………13 6.3 Immunohistochemiscal analysis of the RCC specimen……………………13 6.4 Double Immunofluorescence study on cellular EBP50 expression……………………14 6.5 Statistical analysis…………………………………15 6.6 Image acquisition and processing for presentation…………………………16 6.7 Constructions of Expression Vectors……………………17 6.8 Cell culture and Transfection…………………………………………17 6.9 Transwell Migration Assay …………………………………17 6.10 Wound healing Assay…………………………………………18 6.11 Proliferation Assay………………………………………19 6.12 Flow Cytometry Analysis……………………………………19 7. Results………………………………………………………………20 7.1 The clinicopathological characteristics of 305 RCC patients……………20 7.2 EBP50 accumulated in cytoplasm promotes cell migration.………………24 8. Discussions…………………………………………………………28 9. Reference………………………………………………………… 32 10. Figures………………………………………………………… 35 Figure 1. Characteristics of polyclonal anti-EBP50 antibody (O40) Figure 2. EBP50 expression pattern examined by immunohistochemistry staining Figure 3. Kaplan-Meier analysis of metastasis-free survival in renal cell carcinoma patients according to EBP50 expression patterns Figure 4. Expression level of mutant EBP50 in RCC cell lines Figure 5. Cellular EBP50 expression pattern examined by immunofluorescence staining Figure 6. Effect of mutant EBP50 expression on cell migration Figure 7. Effect of mutant EBP50 expression on wound healing Figure 8. Effect of mutant EBP50 expression on cell viability Figure 9. Effect of mutant EBP50 expression on cell cycle distribution Table 1: Overall clinicopathological characteristics of 305 patients with renal-cell carcinoma Table 2: Clinicopathological manifestations of renal-cell carcinoma patients as categorized by cytosolic EBP50 expression patterns Table 3: Clinicopathological manifestations of renal-cell carcinoma patients as categorized by nuclear EBP50 expression patterns Table 4: Univariate cox regression analysis for metastasis-free, disease-specific and overall survival Table 5: Clinicopathological manifestations of renal-cell carcinoma patients according to characteristic EBP50 expression patterns | |
dc.language.iso | en | |
dc.title | EBP50表現模式與腎細胞癌移轉之關連 | zh_TW |
dc.title | The Correlation between EBP50 Expression Pattern and Metastatic Outcome of Renal Cell Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 周祖述(Tzuu-Shuh Jou) | |
dc.contributor.oralexamcommittee | 蒲永孝(Yeong-Shiau Pu) | |
dc.subject.keyword | 腎細胞癌,轉移,免疫組織化學染色,EBP50, | zh_TW |
dc.subject.keyword | renal cell carcinoma (RCC),Ezrin-radixin-moesin binding phosphoprotein 50 (EBP50 or NHERF1),metastasis,immunohistochemistry (IHC), | en |
dc.relation.page | 49 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-09 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 919.97 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。